1. 首页
  2. 产品目录
  3. 标准品
  4. 药品杂质对照品
  5. 帕立骨化醇杂质

帕立骨化醇杂质D对照品

(1R,3aR,7aR)-1-((2R,5S,E)-5,6-dimethyl-6- ((trimethylsilyl)oxy)hept-3-en-2-yl)-7a- methyloctahydro-4H-inden-4-one （订货以CAS编码或英文名称为准）

创赛科技提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
编号：PC71224
分子式：C22H40O2SI
CAS号：95716-69-1
分子量：364.64
储存条件：-20°C
申请试用
货号 品牌 规格 纯度/含量 标准价 优惠价 库存货期 数量 购买
PC71224-10mg Medlife 10mg
≥95%
 待询 登录后可见
PC71224-25mg Medlife 25mg
≥95%
 待询 登录后可见
PC71224-50mg Medlife 50mg
≥95%
 待询 登录后可见
PC71224-100mg Medlife 100mg
≥95%
 待询 登录后可见
中文名称： 帕立骨化醇中间体CD环
英文名称： (1R,3aR,7aR)-1-((2R,5S,E)-5,6-dimethyl-6- ((trimethylsilyl)oxy)hept-3-en-2-yl)-7a- methyloctahydro-4H-inden-4-one
英文别名： DYLKEUQQJKRJKM-UHFFFAOYSA-N;octahydro-1-(1,4,5-trimethyl-5-trimethylsilyloxy-2-hexenyl)-7a-methyl-4H-inden-4-one;(1R,3aR,7aR)-1-((2R,5S,E)-5,6-dimethyl-6- ((trimethylsilyl)oxy)hept-3-en-2-yl)-7a- methyloctahydro-4H-inden-4-one
CAS号： 95716-69-1
分子式： C22H40O2SI
分子量： 364.64
详细描述 仅用于研发试验中鉴别、检查。95716-69-1|帕立骨化醇杂质D对照品，制备中，详情请联系Medlife客服进行咨询。(1R,3aR,7aR)-1-((2R,5S,E)-5,6-dimethyl-6- ((trimethylsilyl)oxy)hept-3-en-2-yl)-7a- methyloctahydro-4H-inden-4-one可放大生产，批量保障。
搜索质检报告(COA)
相关产品
(1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-5,6-dimethylhepta-3,6-dien-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol
(((1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-5,6-dimethyl-6- ((trimethylsilyl)oxy)hept-3-en-2-yl)-7a-methyloctahydro-4H- inden-4-ylidene)ethylidene)cyc
(5S,7S)-2-(((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)methyl)-1-oxaspiro[2.5]octane-5,7-
(1R,3R)-5-((E)-2-((1R,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyl-2,3,5,6,7,7a-hexahydro-1H-inden-4-yl)vinyl)cyclohexane-1,3-dio
(1R,3R)-5-(2-((1R,3aS,7aR,Z)-1-((2R,5S,E)-6-hydroxy-5,6-dime thylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethy lidene) cyclohexane-1,3-diol
PL-A’:(1R,3aR,7aR)-1-((2R,5R,E)-6-hydroxy-5,6-dimethy lhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-one PL-AS’:(1R,3aR,7aR)-1-((2R,5R,Z)-6-hydroxy-5,
(1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((R,E)-5,6-dimethylhepta-3,5-dien-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol
tert-butyl(((1R,3aR,7aR)-1-((2R,5S,E)-5,6-dimethyl -6-((tetrahydro-2H-pyran-2-yl)oxy)hept-3-en-2-yl) -7a-methyloctahydro-1H-inden-4-yl)oxy)dimethylsil
(3S,6R,E)-6-((1R,3aS,7aR,E)-4-(2-((3R,5R)-3,5-bis ((tert-butyldimethylsilyl)oxy)cyclohexylidene) ethylidene)-7a-methyloctahydro-1H-inden-1-yl)- 2,3-di
PL-A’:(1R,3aR,7aR)-1-((2R,5R,E)-6-hydroxy-5,6-dimethy lhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-one PL-AS’:(1R,3aR,7aR)-1-((2R,5R,Z)-6-hydroxy-5,